• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CONSORT 扩展补充报告规范:中药方剂报告条目(2017 年版):建议、说明与详述(简体中文版)

CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration (Simplified Chinese Version).

机构信息

From Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region, People's Republic of China; Chinese Cochrane Centre and Chinese Evidence-Based Medicine Centre, Sichuan University, Sichuan, People's Republic of China; Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom; and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

出版信息

Ann Intern Med. 2017 Jul 18;167(2):W21-W34. doi: 10.7326/IsTranslatedFrom_M17-2977_2. Epub 2017 Jun 27.

DOI:10.7326/IsTranslatedFrom_M17-2977_2
PMID:28654957
Abstract

Editors' Note: This article is the simplified Chinese version of the CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. (Cheng C, Wu T, Shang H, Li, Y, Altman D, Moher D; CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. Ann Intern Med. 2017;167:112-21. [Epub 27 June 2017]. doi:10.7326/M16-2977).

摘要

编者按

本文是《中医方剂 CONSORT 扩展声明 2017:推荐、说明和详述》的简体中文版本。(程春松,吴泰相,商洪才,李幼平,David Altman,Dimitrios Moher;CONSORT-CHM 方剂 2017 组。中医方剂 CONSORT 扩展声明 2017:推荐、说明和详述。国际内科医学杂志。2017;167:112-21. [电子刊于 2017 年 6 月 27 日]。doi:10.7326/M16-2977)

相似文献

1
CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration (Simplified Chinese Version).CONSORT 扩展补充报告规范:中药方剂报告条目(2017 年版):建议、说明与详述(简体中文版)
Ann Intern Med. 2017 Jul 18;167(2):W21-W34. doi: 10.7326/IsTranslatedFrom_M17-2977_2. Epub 2017 Jun 27.
2
CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration (Traditional Chinese Version).CONSORT 扩展版中草药方剂 2017:建议、说明和详细解释(繁体中文版)。
Ann Intern Med. 2017 Jul 18;167(2):W7-W20. doi: 10.7326/IsTranslatedFrom_M17-2977_1. Epub 2017 Jun 27.
3
CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration.CONSORT 扩展版 2017 年草药方剂报告规范:建议、说明与详述。
Ann Intern Med. 2017 Jun 27;167(2):112-121. doi: 10.7326/M16-2977. Print 2017 Jul 18.
4
The reporting quality of randomized controlled trials in Chinese herbal medicine (CHM) formulas for diabetes based on the consort statement and its extension for CHM formulas.基于CONSORT声明及其针对中药配方的扩展,评估用于糖尿病的中药配方随机对照试验的报告质量。
Front Pharmacol. 2024 Jan 22;15:1288479. doi: 10.3389/fphar.2024.1288479. eCollection 2024.
5
Reporting quality and risk of bias of randomized controlled trials of Chinese herbal medicine for multiple sclerosis.中文草药治疗多发性硬化症的随机对照试验的报告质量和偏倚风险。
Front Immunol. 2024 Aug 19;15:1429895. doi: 10.3389/fimmu.2024.1429895. eCollection 2024.
6
Innovation of clinical trials in China: Commentary on the publication of "CONSORT extension for Chinese herbal medicine formulas 2017: Recommendations, explanation, and elaboration".中国临床试验的创新:评《2017年中药复方临床试验报告规范扩展版:建议、解释与详述》的发表
J Evid Based Med. 2017 Aug;10(3):155-162. doi: 10.1111/jebm.12268.
7
The methodological reporting quality in strictly randomized controlled trials for COVID-19 and precise reporting of Chinese herbal medicine formula intervention.新型冠状病毒肺炎严格随机对照试验的方法学报告质量及中药方剂干预的精准报告
Front Pharmacol. 2025 Mar 31;16:1532290. doi: 10.3389/fphar.2025.1532290. eCollection 2025.
8
Evaluation of compliance of CONSORT-CHM formula 2017 in randomized controlled trials of Chinese herbal medicine formulas: protocol of a five-year review.2017年中药复方随机对照试验中CONSORT-CHM公式依从性的评估:一项五年回顾方案
Front Pharmacol. 2024 Feb 23;15:1287262. doi: 10.3389/fphar.2024.1287262. eCollection 2024.
9
Improving the quality of randomized controlled trials in Chinese herbal medicine, part IV: applying a revised CONSORT checklist to measure reporting quality.提高中医药随机对照试验的质量,第四部分:应用修订后的CONSORT清单衡量报告质量。
Zhong Xi Yi Jie He Xue Bao. 2006 May;4(3):233-42. doi: 10.3736/jcim20060303.
10
Reporting Quality of Randomized Controlled Trials for the Treatment of Eczema with Chinese Patent Medicine Based on the CONSORT-CHM Formulas 2017.基于2017版中成药治疗湿疹随机对照试验的CONSORT-CHM格式报告质量
Evid Based Complement Alternat Med. 2020 Sep 14;2020:2949125. doi: 10.1155/2020/2949125. eCollection 2020.

引用本文的文献

1
The methodological reporting quality in strictly randomized controlled trials for COVID-19 and precise reporting of Chinese herbal medicine formula intervention.新型冠状病毒肺炎严格随机对照试验的方法学报告质量及中药方剂干预的精准报告
Front Pharmacol. 2025 Mar 31;16:1532290. doi: 10.3389/fphar.2025.1532290. eCollection 2025.
2
Traditional Chinese medicine for cardiovascular disease: efficacy and safety.用于心血管疾病的传统中药:疗效与安全性。
Front Cardiovasc Med. 2024 Dec 3;11:1419169. doi: 10.3389/fcvm.2024.1419169. eCollection 2024.
3
Chinese herbal medicine Shenqi compound for early intervention in patients at high cardiovascular risk of type 2 diabetes mellitus: the protocol of a multicenter, randomized, double-blind, placebo-controlled trial.
中药复方参芪复方对2型糖尿病心血管高危患者的早期干预:一项多中心、随机、双盲、安慰剂对照试验方案
Front Cardiovasc Med. 2024 Jan 8;10:1290240. doi: 10.3389/fcvm.2023.1290240. eCollection 2023.
4
The Qi-Bang-Yi-Shen formula ameliorates renal dysfunction and fibrosis in rats with diabetic kidney disease <em>via</em> regulating PI3K/AKT, ERK and PPARγ signaling pathways.芪柏益肾方通过调控 PI3K/AKT、ERK 和 PPARγ 信号通路改善糖尿病肾病大鼠的肾功能和纤维化。
Eur J Histochem. 2023 Mar 1;67(1):3648. doi: 10.4081/ejh.2023.3648.
5
To study the mechanism of panax notoginseng in the treatment of aspirin resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-κB signaling pathway: A study protocol.基于 TLR4/MyD88/NF-κB 信号通路研究三七在脑卒中二级预防中治疗阿司匹林抵抗的作用机制:研究方案。
Medicine (Baltimore). 2022 Dec 16;101(50):e31919. doi: 10.1097/MD.0000000000031919.
6
Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol.参芪消痰方治疗 2 型糖尿病周围动脉硬化症患者的疗效、安全性及作用机制:一项随机、双盲、安慰剂对照试验方案。
BMC Complement Med Ther. 2022 Dec 22;22(1):337. doi: 10.1186/s12906-022-03813-9.
7
Clinical Evidence on the Use of Chinese Herbal Medicine for Acute Infectious Diseases: An Overview of Systematic Reviews.中医药治疗急性传染病的临床证据:系统评价概述
Front Pharmacol. 2022 Feb 25;13:752978. doi: 10.3389/fphar.2022.752978. eCollection 2022.
8
Systematic Review and Meta-Analysis on Randomized Controlled Trials on Efficacy and Safety of Panax Notoginseng Saponins in Treatment of Acute Ischemic Stroke.三七总皂苷治疗急性缺血性脑卒中有效性与安全性的随机对照试验的系统评价与Meta分析
Evid Based Complement Alternat Med. 2021 Jul 9;2021:4694076. doi: 10.1155/2021/4694076. eCollection 2021.
9
A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine.基于整合药理学的研究综述:中医领域的范式转变
Acta Pharm Sin B. 2021 Jun;11(6):1379-1399. doi: 10.1016/j.apsb.2021.03.024. Epub 2021 Mar 20.
10
Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials.中药治疗非酒精性脂肪性肝病的疗效与安全性:随机对照试验的系统文献综述
Chin Med. 2021 Jan 11;16(1):9. doi: 10.1186/s13020-020-00422-x.